Resilience Invests in Pathogen-Killing MicroShield

Resilience Capital Partners has formed a joint venture with MShield Holdings and its affiliate, MShield Healthcare (together MShield), to market MicroShield 360, an antimicrobial coating system.

MicroShield 360 is EPA-registered and FDA-approved and is colorless, odorless, non-toxic and hypoallergenic and reduces microbial contamination of bacteria, viruses, mold, algae, yeast, mildew, fungi and other potentially disease-causing microorganisms.

MicroShield 360 offers protection from a spectrum of pathogens including methicillin-resistant staphylococcus aureus (MRSA), clostridioides difficile (C. diff), escherichia coli (E. coli), Norovirus, numerous flu strains, and enveloped viruses including the common cold and more than 90 additional diseases and conditions.

The protocol for MicroShield 360 requires that an area be cleaned thoroughly prior to a three-step treatment that includes the application of an electrostatic disinfectant, a specially formulated disinfectant and a proprietary coating formula that imparts a final biostatic finish to treated surfaces, preventing pathogens from living on them for up to one year.

Resilience and its joint venture partners will ensure that MicroShield 360 is first provided to participants in the healthcare industry including hospitals, long-term care centers, nursing homes and acute care and assisted living centers. MShield will also develop applications of MicroShield 360 for the consumer, residential and transportation sectors.

“Having come from STERIS, a leader in the sterilization of medical instruments, I know a game-changing active ingredient when I see one,” said David Johnson, chief executive officer of MShield Holdings and president of MShield Healthcare. “It is a privilege to be part of such a solution, and we will be exploring every opportunity to assist not only the healthcare industry but also other sectors that can be affected by the spread of communicable diseases.”

“Innovation comes in all forms, including how you disinfect hospitals, healthcare facilities and other venues,” said Steven Rosen, co-CEO of Resilience. “We see that in MicroShield 360, which kills 99.99 percent of all pathogens, perfection is difficult to achieve in any endeavor, but this is about as close as you’ll find, and it is why we are putting considerable financial resources towards making MicroShield 360 readily available. With growing concern over pathogens, we look forward to working with the Kubec family, which pioneered this concept through MicroShield, to make it affordable, build out distribution channels and deliver this product to those in need in the current crisis environment.”

“MicroShield 360 offers tremendous potential for reducing the transmission of disease-causing microorganisms, and we look forward to helping make MicroShield 360 widely available to protect public health in these uncertain times,” added Mr. Rosen.

Resilience Capital Partners invests from $10 million to $40 million in middle-market companies with $25 million to $250 million in revenues and EBITDA typically under $20 million. Sectors of interest include industrial manufacturing, distribution, business services, aviation & aerospace, minerals & mining, consumer goods, transportation logistics, building products, metals, and capital equipment. The firm was founded in 2001 and is based in Cleveland.

© 2020 Private Equity Professional | March 24, 2020

Print Friendly, PDF & Email